Ovarian cancer is the leading cause of death attributed to gynecologic malignancies for women in the U.S. [1]. The standard approach for treating ovarian cancer is debulking surgery followed by combination platinum and taxane che- motherapy, usually carboplatin and paclitaxel [2–5]. Intra- peritoneal cisplatin and intravenous paclitaxel have further augmented response and time to progression, and pushed the median survival to 5 years for optimally resected pa- tients [6].